Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Burkitt Lymphoma 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Rituximab 4ibrutinib 2fludarabine phosphate 2fludarabine 2blinatumomab 2Vorinostat 2Radiation 2Nivolumab 2Lenalidomide 2Gemcitabine 2Cytarabine 2Cyclophosphamide 2CT-P10 2umbralisib 1ublituximab 1tafasitamab 1polatuzumab vedotin 1pembrolizumab 1ofatumumab 1molibresib 1magrolimab 1iberdomide 1glofitamab 1entinostat 1cirmtuzumab 1carmustine, poliferprosan 20 drug combination 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Tacrolimus 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell × Asparaginase × Clear all
NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡